Gilead Sciences, Inc. (GILD) — closed signal from January 7, 2026
Target reached Published before the outcome was known, scored automatically when the window closed on April 7, 2026.
Predicted vs. what happened
What happened
Reached its target in 19 days.
The thesis — published January 7, 2026
Gilead is a relatively steady healthcare pick to help protect a portfolio if markets get rough. The company announced a research deal with OncoNano about a drug-delivery method that could bring future payments. Investors are also watching its cancer drug programs such as TIGIT. The plan here is to buy on small price drops in a big, liquid company rather than chase fast gains.
Primary drivers
- New collaboration could add future drug possibilities
- Cancer programs may draw investor attention to the stock
- Seen as more stable if investors get nervous
- Buying dips suits a steady, cautious approach
How it played out
GILD: target reached in 19 days
Lyra published GILD at $124.20 on 2026-01-07 for a short-term window ending 2026-04-07. The thesis expected 10% growth and a target of $136.62. It pointed to a new OncoNano collaboration, cancer programs such as TIGIT, the stock's steadier healthcare profile if markets got rough, and a plan to buy small price drops rather than chase fast gains.
Inside the window, GILD rose past the target. It peaked at $157.29 on 2026-02-11, with a 26.6% peak gain, and reached the target in 19 days. It ended the window at $138.80, still above the target. The thesis played out.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.